Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (脑动极光-B, 06681) has seen significant stock activity, with shareholders depositing shares into Guotai Junan (Hong Kong), resulting in a market value of HKD 2.729 billion, accounting for 33.31% of the total [1] Group 2 - For the six months ending June 30, 2025, Brainstorm Cell Therapeutics reported revenue of HKD 100 million, representing a year-on-year increase of 92.82% [1] - The adjusted net loss for the company was HKD 88.022 million, which is an increase of 11.64% compared to the previous year [1] - The loss attributable to the company's owners was HKD 126 million, reflecting a year-on-year increase of 10.53%, with a loss per share of HKD 0.11 [1]
脑动极光-B股东将股票存入国泰君安(香港) 存仓市值27.29亿港元